Answers are grounded in this paper and cite their sources.
Low BRCA1 expression in primary sporadic ovarian carcinoma is associated with prolonged survival. Recurrent ovarian carcinomas commonly have increased BRCA1 and/or BRCA2 protein expression post chemotherapy exposure which could mediate resistance to platinum based therapies. However, alterations in expression of these proteins after chemotherapy are not commonly mediated by promoter methylation, and other regulatory mechanisms are likely to contribute to these alterations.
No takes yet. Share an insight, caveat, or question.
Swisher et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: